US 12,246,003 B2
Methods of reducing the risk of cardiovascular events in a subject
Paresh Soni, Mystic, CT (US)
Assigned to AMARIN PHARMACEUTICALS IRELAND LIMITED, Dublin (IE)
Filed by Amarin Pharmaceuticals Ireland Limited, Dubin (IE)
Filed on Apr. 8, 2022, as Appl. No. 17/716,708.
Application 17/716,708 is a continuation of application No. 17/400,428, filed on Aug. 12, 2021, granted, now 11,298,333.
Application 17/400,428 is a continuation of application No. 17/165,688, filed on Feb. 2, 2021, granted, now 11,116,743, issued on Sep. 14, 2021.
Application 17/165,688 is a continuation of application No. 17/153,606, filed on Jan. 20, 2021, granted, now 11,116,742, issued on Sep. 14, 2021.
Application 17/153,606 is a continuation of application No. 17/126,619, filed on Dec. 18, 2020, granted, now 11,717,504.
Application 17/126,619 is a continuation of application No. 16/927,224, filed on Jul. 13, 2020, granted, now 11,000,499, issued on May 11, 2021.
Application 16/927,224 is a continuation of application No. 16/736,936, filed on Jan. 8, 2020, granted, now 10,786,478.
Application 16/736,936 is a continuation of application No. 16/574,415, filed on Sep. 18, 2019, abandoned.
Application 16/574,415 is a continuation of application No. 16/391,128, filed on Apr. 22, 2019, granted, now 10,668,042, issued on Jun. 2, 2020.
Claims priority of provisional application 62/818,514, filed on Mar. 14, 2019.
Claims priority of provisional application 62/813,888, filed on Mar. 5, 2019.
Claims priority of provisional application 62/758,387, filed on Nov. 9, 2018.
Claims priority of provisional application 62/735,680, filed on Sep. 24, 2018.
Claims priority of provisional application 62/735,670, filed on Sep. 24, 2018.
Prior Publication US 2023/0105054 A1, Apr. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/232 (2006.01); A61K 9/00 (2006.01); A61K 31/40 (2006.01); A61K 31/505 (2006.01); A61P 9/10 (2006.01)
CPC A61K 31/232 (2013.01) [A61K 9/0053 (2013.01); A61P 9/10 (2018.01); A61K 31/40 (2013.01); A61K 31/505 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method of reducing risk of one or more of: myocardial infarction, stroke, cardiovascular death, unstable angina, coronary revascularization procedures and/or hospitalizations for unstable angina in a subject on statin therapy and with an established cardiovascular disease, the method comprising administering to the subject a composition comprising eicosapentaenoic acid per day, wherein during the course of treatment the subject is monitored for symptoms of atrial fibrillation and/or flutter.